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Abstract
Objective: To estimate the prevalence of adult ADHD diagnosis and treatment in U.S. Medicaid beneficiaries. Method:
Using outpatient, inpatient, and pharmacy billing records for patients eligible for Medicaid fee-for-service benefits within 29
states from 1999 to 2010, we estimated the annual prevalence of ADHD diagnosis and treatment. Results: The prevalence
of ADHD diagnosis increased from 2.20 per 1,000 patients in 1999 to 10.57 in 2010. Likewise, prevalence of ADHD
treatment increased from 1.95 per 1,000 patients in 1999 to 13.16 in 2010. Between 40% and 65%, patients had ADHD
drug prescription fills 6 months after ADHD diagnosis, whereas 45% to 55% of the beneficiaries with an ADHD drug
prescription fill had ADHD diagnoses within 6 months before the prescription. Conclusion: In publicly insured adults, the
prevalence of ADHD diagnosis and treatment increased dramatically over the years. Approximately half of the diagnosed
patients are not treated, whereas half of the treated adults are not diagnosed. (J. of Att. Dis. 2018; 22(2) 182-190)
Keywords
ADHD, central nervous system stimulants, disease prevalence, epidemiology

Background
ADHD has been considered a childhood neurodevelopmental disorder, characterized by symptoms, including inattention, impulsivity, and hyperactivity (Davidson, 2008;
Goldman, Genel, Bezman, & Slanetz, 1998). In recent
years, evidence has shown that in 30% to 70% of patients
with ADHD during childhood, the disorder persists into
adulthood (Lara et al., 2009; Mannuzza, Klein, & Moulton,
2003; Pary et al., 2002; Silver, 2000). Different from presentation of this disorder in children, symptoms of hyperactivity among adults with ADHD diminish, whereas
symptoms of inattention persist and may affect important
functions in life. Adult patients with ADHD may also experience interpersonal problems and coexisting psychiatric
and substance abuse disorders (Volkow & Swanson, 2013).
Considering the significant consequences of ADHD among
adults, it is important to examine the epidemiology of the
diagnosis and treatment of ADHD in adults.
Although ADHD is well studied in the pediatric population, little is known about ADHD diagnosis and treatment in
adults. Reported prevalence rates of diagnosed ADHD
among adults vary across a limited number of available
studies, which have used different methodological
approaches and different samples of patients (Almeida
Montes, Hernández García, & Ricardo-Garcell, 2007;
Faraone & Biederman, 2005; Heiligenstein, Conyers,
Berns, Miller, & Smith, 1998; Holden et al., 2013; Kessler

et al., 2006; Knight et al., 2014; McCarthy et al., 2012;
Montejano, Sasané, Hodgkins, Russo, & Huse, 2011;
Simon, Czobor, Bálint, Mészáros, & Bitter, 2009). Early
studies of small sample size estimate the prevalence of
ADHD diagnosis mainly by examining self-reported symptoms or via structured interviews based on the Diagnostic
and Statistical Manual of Mental Disorders (4th ed.;
DSM-IV; American Psychiatric Association [APA], 1994)
criteria (Almeida Montes et al., 2007; Faraone & Biederman,
2005; Heiligenstein et al., 1998; Kessler et al., 2006;
McCarthy et al., 2012; Simon et al., 2009). To date, limited
number of studies have reported population-based estimates
in adults (Holden et al., 2013; Knight et al., 2014; McCarthy
et al., 2012; Montejano et al., 2011), and no study has estimated the prevalence of ADHD diagnosis and treatment in
adult Medicaid beneficiaries. Furthermore, most population-based studies have required presence of both ADHD
diagnosis and treatment to determine the prevalence of the
disorder, which may underestimate true prevalence, as
treatment discontinuation is common. In terms of the
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Table 1. Numerator and Denominator Definitions for Prevalence Estimates.
Prevalence/percentage
Annual prevalence of ADHD
Annual prevalence of ADHD drug use
Percentage of patients who had
ADHD prescription claims 6 months
after ADHD diagnosis
Percentage of patients who had
ADHD diagnosis 6 months before
their ADHD prescription claim

Numerator

Denominator

Number of patients with ≥1 inpatient
or 2 outpatient ADHD diagnoses
Number of patients with ≥1 ADHD
prescription claim
Number of patients with ≥1 ADHD
prescription claim within 6 months of
follow-up
Number of patients with ≥1 in- and
2 outpatient ADHD diagnoses 6
months before prescription claim

Number of adults with 12-month continuous
eligibility in Year X
Number of adults with 12-month continuous
eligibility in Year X
Number of eligible ADHD patients with
6-month continuous eligibility after ADHD
diagnosis in the first half of Year X
Number of eligible patients with 6-month
continuous eligibility 6 months before ADHD
prescription claim in the second half of Year X

prevalence of ADHD treatment among adults, majority of
the previous studies only reported prevalence of treatment
in young adults (age ≤20; Barry, Martin, & Busch, 2012;
Johansen, Matic, & McAlearney, 2015; McCarthy et al.,
2009). Only one study reported ADHD treatment rate in
adults aged 20 years and older (Castle, Aubert, Verbrugge,
Khalid, & Epstein, 2007).
To address the gaps in the existing literature, the goal of
this study was to estimate the prevalence of diagnosed adult
ADHD and its treatment in U.S. Medicaid beneficiaries, as
well as to examine proximate relationships between prescribing ADHD medications and ADHD diagnosis.

Method
Study Design
We conducted a repeated cross-sectional study using
Medicaid Analytic eXtract (MAX) files of 29 states to
identify all adult Medicaid beneficiaries in fee-for-service
(FFS) and primary care case management (PCCM) plans
aged 18 to 64 years. The MAX data are a set of patientlevel data files that provide monthly information on
patients’ Medicaid eligibility, demographics, diagnoses,
and medical procedures performed at outpatient and inpatient settings as well as medication dispensing records submitted for reimbursement.

Definitions
ADHD patients were identified based on having at least one
inpatient or two outpatient visits with International
Classification of Disease, Version 9, Clinical Modification
(ICD-9-CM) diagnosis code of 314.xx (314.00—attention
deficit disorder without mention of hyperactivity, 314.01—
attention deficit disorder with hyperactivity, 314.1—hyperkinesis with developmental delay, 314.2—hyperkinetic
conduct disorder, 314.8—other specified manifestations of
hyperkinetic syndrome, and 314.9—unspecified hyperkinetic syndrome) in each specific study year.

ADHD medication use was determined based on having
at least one prescription fill record of an ADHD medication.
ADHD medications included all dosage forms of methylphenidate, mixed amphetamine salts, pemoline, and the
nonstimulant medication atomoxetine.

Statistical Analysis
We report four estimates involving ADHD diagnosis and
treatment using different eligibility requirements, and
numerator and denominator definitions (Table 1). For each
year from 1999 through 2010, we identified all individuals
18 to 64 years old who were continuously enrolled in
Medicaid for the entire 12 months of the measurement year
(e.g., from January 1-December 31, 2001). The annual
prevalence of ADHD was then calculated as the proportion
of eligible patients who had at least one inpatient or two
outpatient service claims with ICD-9-CM code 314.xx. The
annual prevalence of ADHD medication use was calculated
as the proportion of eligible patients who had at least one
pharmacy claim for an ADHD medication in the study year.
We stratified estimates of ADHD diagnosis and ADHD
medication use prevalence by age and gender, and the prevalence of ADHD medication use by methylphenidate,
mixed amphetamine salts, and atomoxetine preparations.
To estimate the prevalence of treatment in patients with
diagnosed ADHD, we identified patients who had at least
one inpatient or two outpatient service claims with ICD9-CM code 314.xx in the first half of the calendar year (i.e.,
January 1-June 30). We then followed these patients for 6
months starting from the date of their ADHD diagnosis to
determine the proportion of patients who had at least one
pharmacy claim for an ADHD medication during the follow-up period. In each annual cohort, eligible patients were
required to have at least 6 months of continuous eligibility
after the date of their first ADHD diagnosis. Reversing the
approach of the previous analysis, we also estimated the
proportion of patients who had at least one ADHD diagnosis in the 6-month period before their first dispensing of an
ADHD medication in the second half of a calendar year
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Table 2. Demographic Characteristics of Study Samples by Year.
Year
Characteristics

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

Sample size (n)
Age (%)
18-25
26-35
36-45
46-55
55 and older
Gender (%)
Male
Female

1,952,942
39.75
18.36
21.62
22.84
19.41
17.76

2,035,380
39.86
18.05
21.27
23.14
20.05
17.48

2,178,294
39.21
19.79
21.74
22.59
19.76
16.12

2,171,520
39.23
19.33
22.01
22.86
19.98
15.82

2,571,952
39.22
19.66
21.87
22.27
20.30
15.90

2,462,090
39.12
20.00
22.05
21.71
20.49
15.75

2,275,483
39.03
20.26
22.27
21.06
20.66
15.74

1,775,431
40.29
18.67
19.72
20.44
23.11
18.06

1,437,463
40.39
19.12
19.33
19.45
23.29
18.80

1,342,189
39.92
20.14
20.16
18.66
22.89
18.16

1,288,942
39.86
19.10
21.40
19.10
22.91
17.49

1,313,374
39.43
19.75
22.30
18.63
22.61
16.70

35.08
64.92

35.16
64.84

34.22
65.78

34.89
65.11

34.96
65.04

35.14
64.86

35.11
64.89

37.90
62.10

38.55
61.45

38.35
61.65

39.33
60.67

39.88
60.12

14

12

10
Prevalence (per 1,000)

(i.e., July 1-December 31). Thus, in each calendar year, we
required eligible patients to have at least 6 months of continuous enrollment before their first ADHD treatment pharmacy claim.
SAS Version 9.4 (SAS Institute, Cary, North Carolina)
was used to perform the data management and statistical
analyses. The study was approved by the Institutional
Review and Privacy Boards at the University of Florida and
the Centers for Medicare & Medicaid Services.
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Figure 1. Annual ADHD diagnosis and medication use
prevalence among adults.
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From 1999 to 2010, we identified approximately 1,288,942 to
2,571,952 eligible adults in each year, with 34.22% to 39.88%
females and the average age ranged from 39.03 to 40.39 years
(Table 2). The prevalence of adult ADHD diagnosis increased
approximately fivefold from 2.20 per 1,000 patients in 1999 to
10.57 per 1,000 patients in 2010 (Figure 1). Likewise, the prevalence of ADHD treatment increased considerably from 1.95
per 1,000 patients in 1998 to 13.16 per 1,000 patients in 2010
(Figure 1). Notably, in the later study years, the annual prevalence of ADHD treatment use surpassed the ADHD prevalence. Overall, the prevalence estimates of ADHD diagnosis
and ADHD medication use increased across all age groups
from 1999 to 2010 (Figures 2 and 3). Prevalence of both diagnosis and medication use showed a consistent age trend with
the largest prevalence in younger age groups. Compared with
females, male patients showed higher prevalences of both
ADHD diagnosis and medication use, but the prevalence rate
ratio for females comparing prevalence in 2010 to prevalence
in 1999 was slightly higher than that of males, with 5.6 versus
3.9 for ADHD diagnosis and 7.6 versus 5.9 for ADHD medication use (Figure 4).
Comparing utilization pattern of the various ADHD
medications, the prevalence of methylphenidate use
increased from 1.21 per 1,000 patients in 1999 to 4.50 per
1,000 patients in 2010, whereas the prevalence of mixed
amphetamine salts use increased disproportionally from
0.50 per 1,000 patients in 1999 to 6.98 per 1,000 patients in
2010 (Figure 5). The prevalence of atomoxetine use

8

2.5
2
1.5
1
0.5
0
1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

Year
Age (18-25)

Age (26-35)

Age (36-45)

Age (46-55)

Age (56+)

Figure 2. Annual ADHD diagnosis prevalence among adults by
age groups.

increased from 0.90 per 1,000 patients in 2003 to a peak
with 2.23 per 1,000 patients in 2005, which was followed
by a decrease to 1.68 per 1,000 patients in 2010.
Over the study period, approximately 40% to 65% of
patients with an ADHD diagnosis in the first half of the
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Figure 3. Annual ADHD medication use prevalence among
adults by age groups.
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Figure 4. Annual ADHD diagnosis and medication use
prevalence among adults by gender.

calendar year had at least one ADHD prescription fill claim
in 29 U.S. states. Likewise, about 44% to 52% of all patients
who filled an ADHD prescription had at least one inpatient
or two outpatient service claims with a diagnosis of 314.xx
during the 6 months before their ADHD prescription (Figure
6). Both percentages increased over the years.

Discussion
This study examined the prevalence of ADHD diagnosis and
treatment among adult Medicaid beneficiaries. The study
results highlight four important insights in ADHD diagnosis
and medication use among adults. First, in this study, the
prevalence estimates of ADHD diagnosis were about twice
of the estimates in previous studies using administrative
databases in various geographic areas of the United States
(Knight et al., 2014; Montejano et al., 2011). In a U.S. commercial population with employer-sponsored insurance,
the estimated prevalence was about 1.20 to 4.02 per 1,000
patients from 2002 to 2007 (Montejano et al., 2011). The

other study reported the prevalence of ADHD in a managed
care population at 3.12 to 4.15 per 1,000 patients from 2006
to 2009 (Knight et al., 2014). This could be partially
explained by the different study populations. Compared with
privately insured patients, Medicaid beneficiaries in general
are of lower social economic status, which has been shown
to be one of the causes or the consequences of mental disorders (Hudson, 2005; Miech, Caspi, Moffitt, Wright, & Silva,
1999). However, the higher prevalence rate we observed
may be in part explained by different case definition such as
the requirement to have both a diagnosis and pharmacological ADHD treatment in the previous studies (Knight et al.,
2014). To avoid underestimating the prevalence caused by
untreated ADHD among adults, we did not use prescription
claims in addition to diagnosis claims to determine manifestation of ADHD. When analyzing the proximity of diagnosis
and treatment, we observed that only about 40% to 65% of
the diagnosed patients had ADHD treatment within 6 months
after diagnosis, which confirmed our concerns for untreated
adult ADHD. Our findings provided insights on the measurement of ADHD diagnosis among adults using automated
databases in future research, which should take how adult
ADHD and treatment were diagnosed and treated in the
actual clinical setting into consideration. During the study
periods of the existing studies on adult ADHD, including
this study, the diagnosis of adult ADHD was guided by the
DSM-IV. However, DSM-IV was criticized because the diagnostic criteria for ADHD were primarily focused on children, which leads to underdiagnosis of many teens and
adults with symptoms of ADHD (APA, 1994; Applegate
et al., 1997). In 2013, Diagnostic and Statistical Manual of
Mental Disorders (5th ed.; DSM-5; APA, 2013) was updated
according to the evidence of the reduction in symptoms with
increasing age. Adults as well as teens can now be diagnosed
more easily because DSM-5 raises the age limit of when
symptoms should be documented, that is, from age 7 to age
12 and lowers the number of symptoms from 6 to 5 for diagnosis in individuals of age 17 and above (APA, 2013). With
the implementation of DSM-5, the prevalence of adult
ADHD after 2013 will be expected to be higher from what
has been reported (Ghanizadeh, 2013).
Second, similar to other studies, we observed a substantial increase in both the prevalence rates of ADHD diagnosis and treatment among adult Medicaid beneficiaries
(Holden et al., 2013; Knight et al., 2014; McCarthy et al.,
2012; Montejano et al., 2011). In this study, we observed an
approximately five fold relative increase in ADHD diagnosis and a seven fold relative increase in ADHD treatment in
adult patients. This substantial increase in diagnosis of
ADHD in adults could partially be explained by the fact that
the prevalence of ADHD may have been influenced by
modified diagnostic criteria among adults over time
(Wender, Wolf, & Wasserstein, 2001). Furthermore, our
findings reflect the increasing clinician and public recognition of ADHD as a serious medical condition for adults and
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Figure 5. Annual prevalence of methylphenidate, mixed amphetamine salts, and atomoxetine preparations use.
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Figure 6. Percentage of patients with ADHD medication after ADHD diagnosis and percentage of patients who had ADHD diagnosis
before ADHD medication.

also raise concerns about the potential growth of the medical and economic burden related to ADHD in adults, especially in patients with low social economic status. In terms
of prevalence of specific drug classes, mixed amphetamine
salts had surpassed methylphenidate utilization at the end of
the study period, where the prevalence of mixed amphetamine salts was one and a half times as large as the prevalence of methylphenidate. Atomoxetine use was on the
decline across all 29 states with marginal prevalence rates
in 2010. The fluctuation of the prevalence of atomoxetine

use corresponds with the box warning issued by the Food
and Drug Administration (FDA) for the potential side effect
related to suicidal behavior/ideation in September 2005.
Third, the growth of ADHD diagnosis and treatment
occurred across both genders and all age groups over the
12-year study period. Compared with males, the prevalence
of both diagnosis and treatment among females was lower,
which were similar to what has been observed in children
(Winterstein et al., 2008). However, the prevalence in females
increased slightly faster than that in males. Compared with
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older age groups, the highest prevalence in 18 to 25 age
group can be explained by delayed diagnosis from childhood,
persistence of ADHD from childhood, as well as the increased
recognition and diagnosis of ADHD in the college-age population. Some argue that the lower prevalence in older age
groups could also be explained by improvement of hyperactivity and impulsivity and increased compensation strategies
over time (Biederman, Wilens, Spencer, & Adler, 2007;
Jackson & Farrugia, 1997; Klein et al., 2012). However,
according to survey-based studies using validated diagnostic
tools, the prevalence of ADHD was estimated to be more
than 3% among older adults (aged >55), which is much
higher than the prevalence we observed (de Zwaan et al.,
2012; Goodman, Mitchell, Rhodewalt, & Surman, 2016;
Guldberg-Kjär & Johansson, 2009; Michielsen et al., 2012).
This suggests the relative absence of diagnosis and treatment
of ADHD in patients above age 55 is much likely a reflection
of lack of clinician training, appropriate symptom definitions, and diagnostic tools for use among older adults in clinical practice.
Finally, the annual prevalence of ADHD treatment use
surpassed the ADHD prevalence in the later study years.
Following the observation, about half of the patients who
had ADHD treatment did not have a service claim with a
diagnosis of 314.xx within 6 months before the pharmacy to
dispense claim, which could be explained by a few possible
reasons. First, studies have shown that physicians may be
reluctant to label adult patients with psychiatric disorders
without confirming the condition (Mitchell, 2007). ADHD
medications are likely to be prescribed when a clinician is
unsure of the diagnosis and uses the medication response as
a clinical indicator of the condition, which may result in
treatment without ADHD diagnosis. In addition, with only
two diagnoses that are documented with an outpatient visit
claim, it is conceivable that more prominent or more acute
diagnoses took precedence, and thus, ADHD may have
been present but not documented. On the contrary, ADHD
medications may be prescribed for narcolepsy or off-label
indications such as treatment-refractory depression, cancer
fatigue, obesity, or other conditions symptomatic with a
lack of motivation and apathy (Greenhill et al., 2002; Jeffers
& Benotsch, 2014; Trenque, Herlem, Abou Taam, & Drame,
2014). Given that previous studies reported prevalent nonmedical use and misuse of prescription stimulants among
young adults (Kaye & Darke, 2012; McCabe, Knight, Teter,
& Wechsler, 2005; Wilens et al., 2008), future research
should address what alternative indications or purposes for
ADHD medication use exist in this population.

Limitation
Our study is subject to a few limitations. In this study, we
used ICD-9-CM diagnosis codes to identify ADHD

diagnosis in medical encounter billing records, which has
inherent limitations due to coding and billing errors. In addition, the accuracy of ADHD diagnosis depends on a number
of factors, including clinician training and experience, time
necessary for adequate evaluation of patients’ condition, as
well as outside informants to increase specificity and sensitivity of diagnosis (Asherson et al., 2010; Moncrieff &
Timimi, 2010; Surman & Goodman, 2017). Thus, our prevalence estimate of ADHD diagnosis may not reflect the true
prevalence among adults. Furthermore, we included patients
from 29 states in the United States, representing the vast
majority of patients enrolled in Medicaid FFS plans nationally. We did not examine the prevalence in individual states
and given demonstrated variability of ADHD diagnoses and
treatment across states in children (Visser et al., 2015;
Visser et al., 2014), we caution against extrapolating our
results to individual states. Of note, sample sizes dropped
drastically in the year 2006 because of increasing Medicaid
managed care penetration and decreased number of FFS
enrollees (Centers for Medicare & Medicaid Services,
2013). In the present analysis, we restricted eligible beneficiaries to those in FFS or PCCM plans from 1999 to 2010
with no supplemental managed care plan other than dental
because of concerns on completeness and quality of the
encounter data of managed care plan. Thus, our results may
have limited generalizability to Medicaid patients in other
managed care plans.

Conclusion
In summary, this study reports the prevalence estimates of
ADHD diagnosis and treatment using administrative data in
Medicaid Analytic eXtract (MAX) billing records. The
prevalence of adult ADHD diagnosis and medication use
has increased substantially from 1999 to 2010 across both
genders and all age groups. Approximately, half of the
patients did not have a prescription claim within 6 months
of the diagnosis whereas half of the patients on ADHD
medications did not have a diagnosis 6 months before the
treatment. These findings on ADHD diagnosis and treatment emphasize the need for studies that examine the treatment patterns of Adult ADHD and alternative diagnosis and
purpose of ADHD medication use.
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